IFN-α2b has long been used in standardized adjuvant therapy for stage IIB/III melanoma patients, which has been proven by the E1684, E1690, E1694, and E2696 trials of adjuvant high-dose interferon (HDI) with extended RFS compared with observations in approximately 2000 patients [3,29,30]. The gene discussed is IFNA2; the disease is melanoma.